The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Fracture risk with intermittent high‐dose oral glucocorticoid therapy
Abstract
Objective: To evaluate the risk of fracture in patients receiving intermittent therapy with high‐dose oral glucocorticoids (GCs). Methods: The study group comprised 191,752 patients from the UK General Practice Database who were 40 years of age and older and received therapy with GCs. The followup time period was divided into the categories of “current” and “no exposure.” The daily dose and cumulative dose for each time period were determined. Relative risks were estimated using Cox proportional hazards models, adjusted for age, sex, body mass index, smoking, disease history, and drug history. Fractures of the radius/ulna, humerus, rib, femur/hip, pelvis, or vertebrae were included in the evaluation. Results: Patients who intermittently received high‐dose GCs (daily dose ≥15 mg) and had no or little previous exposure to GCs (cumulative exposure ≤1 gm) had a small increased risk of osteoporotic (but not hip/femur) fracture; this risk increased substantially with increasing cumulative exposure. Among patients who received a daily dose ≥30 mg and whose cumulative exposure was >5 gm, the relative risk (RR) of osteoporotic fracture was 3.63 (95% confidence interval [95% CI] 2.54–5.20), the RR of fracture of the hip/femur was 3.13 (95% CI 1.49–6.59), and the RR of vertebral fracture was 14.42 (95% CI 8.29–25.08). Conclusion: Intermittent use of high‐dose oral GCs (daily dose ≥15 mg and cumulative exposure ≤1 gm) may result in a small increased risk of osteoporotic fracture. Conversely, patients who receive several courses of high‐dose GCs (daily dose ≥15 mg and cumulative exposure >1 gm) have a substantially increased risk of fracture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
Use of Inhaled Corticosteroids and Risk of Fractures
Van Staa, T. P., Leufkens, H. G. M., & Cooper, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,308
Self-citationUse of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Self-citationDose-Response and Trend Analysis in Epidemiology: Alternatives to Categorical Analysis
Greenland, S. (1995) · Epidemiology · doi:10.1097/00001648-199507000-00005 · Cited by 1,085
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Rheumatology · doi:10.1093/rheumatology/39.12.1383 · Cited by 696
Self-citationThe UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 623
Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559
Self-citation
Cited by
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
Glucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Buckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., Humphrey, M. B., Lane, N. E., Magrey, M., Miller, M., et al. (2017) · Arthritis Care & Research · doi:10.1002/acr.23279 · Cited by 579
Buckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., Humphrey, M. B., Lane, N. E., Magrey, M., Miller, M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40137 · Cited by 527
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment
Chotiyarnwong, P., & McCloskey, E. V. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0341-0 · Cited by 489
Glucocorticoid-induced osteoporosis: an update
Compston, J. (2018) · Endocrine · doi:10.1007/s12020-018-1588-2 · Cited by 471
Glucocorticoid-Induced Osteoporosis
Buckley, L., & Humphrey, M. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1800214 · Cited by 438
The epidemiology of glucocorticoid-associated adverse events
McDonough, A. K., Curtis, J. R., & Saag, K. G. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f51031 · Cited by 405
Glucocorticoid-Induced Osteoporosis and Osteonecrosis
Weinstein, R. S. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.004 · Cited by 364
MacLeod, M., Papi, A., Contoli, M., Beghé, B., Celli, B. R., Wedzicha, J. A., & Fabbri, L. M. (2021) · Respirology · doi:10.1111/resp.14041 · Cited by 359
Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1958-1 · Cited by 335
Self-citationMANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & Canalis, E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 331
Manson, S. C., Brown, R. E., Cerulli, A., & Vidaurre, C. F. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.01.003 · Cited by 269
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review
Sarnes, E., Crofford, L., Watson, M., Dennis, G., Kan, H., & Bass, D. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.009 · Cited by 258
Understanding and managing corticosteroid-induced osteoporosis
Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N., & Adachi, J. D. (2021) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s282606 · Cited by 84
Glucocorticoid-induced osteoporosis
Silverman, S. L., & Lane, N. E. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0005-4 · Cited by 50
When do the risks of repeated courses of corticosteroids exceed the risks of surgery?
Leung, R. M., Dinnie, K., & Smith, T. L. (2014) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21377 · Cited by 49
Rittweger, J., Debevec, T., Frings-Meuthen, P., Lau, P., Mittag, U., Ganse, B., Ferstl, P. G., Simpson, E. J., Macdonald, I. A., Eiken, O., et al. (2016) · Bone · doi:10.1016/j.bone.2016.07.013 · Cited by 35
Metadata
- Authors
- De Vries, F., Bracke, M., Leufkens, H. G. M., Lammers, J. J., Cooper, C., & Van Staa, T. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 56
- Issue
- 1
- Pages
- 208-214
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1989553857
- Cited by
- 298
- References
- 22
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.